Francois Nader, M.D., has been a director of Alexion since November 2017. Dr. Nader served as President, Chief Executive Officer, and Executive Director of NPS Pharma, a global biotechnology company that was focused on delivering innovative therapies to patients with rare diseases, from 2008 to 2015. Prior to NPS, Dr. Nader was a venture partner at Care Capital, a venture capital firm. He previously served on the North America Leadership Team of Aventis Pharma and its predecessor companies, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. He also led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader currently serves as non-executive chairman of Acceleron Pharma, Inc. and on the boards of Advanced Accelerator Applications, Clementia Pharmaceuticals Inc., and private company ArRETT Neuroscience.

Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon and a physician executive MBA from the University of Tennessee.

Dr. Nader is a member of the Audit and Finance Committee and the Science and Innovation Committee.